Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)

被引：0
|
作者：
Fox, E. [1 ]
Wray, S. [2 ]
Shubin, R. [3 ]
Lovett-Racke, A. [4 ]
Huang, D. [5 ]
Bass, A. [6 ]
Weiss, M. [7 ]
Power, S. [7 ]
Bosco, J. [7 ]
Mok, K. [7 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Hope Neurol, Knoxville, TN USA
[3] Arcadia Neurol Ctr, Arcardia, CA USA
[4] Ohio State Univ, Dept Microbial Infect & Immun, Columbus, OH 43210 USA
[5] Mt Carmel Hlth Syst, Ctr Multiple Sclerosis, Westerville, OH USA
[6] Neurol Ctr San Antonio, San Antonio, TX USA
[7] TG Therapeut, New York, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1023
引用
收藏
页码：543 / 544
页数：2
相关论文
共 50 条
  • [41] Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study
    Giovannoni, Gavin
    Boyko, Alexey
    Correale, Jorge
    Edan, Gilles
    Freedman, Mark S.
    Montalban, Xavier
    Rammohan, Kottil
    Stefoski, Dusan
    Yamout, Bassem
    Leist, Thomas
    Aydemir, Aida
    Borsi, Laszlo
    di Cantogno, Elisabetta Verdun
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (06) : 719 - 730
  • [42] Cause of death in multiple sclerosis patients from a 21-year long-term follow-up study
    Ebers, G.
    Cutter, G.
    Rametta, M.
    Reder, A.
    Goodin, D.
    Kremenchutzky, M.
    Oger, J.
    Beckmann, K.
    Knappertz, V.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S412 - S413
  • [43] CAUSE OF DEATH IN MULTIPLE SCLEROSIS PATIENTS FROM THE 21-YEAR LONG-TERM FOLLOW-UP STUDY
    Ebers, G. C.
    Cook, S.
    Cutter, G.
    Goodin, D. S.
    Reder, A. T.
    Kremenchutzky, M.
    Oger, J.
    Rametta, M.
    Beckmann, K.
    Bogumil, T.
    Knappertz, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 60 - 60
  • [44] Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies: Results From the OLIKOS Study
    Hua, Le
    Brown, Brandon
    Camacho, Elizabeth
    Greenberg, Benjamin M.
    Henry, Roland
    Houtsma, Erik
    Alvarez, Enrique
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1167 - 1168
  • [45] Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis
    Montalban, Xavier
    Comi, Giancarlo
    Antel, Jack
    O'Connor, Paul
    de Vera, Ana
    Cremer, Malika
    Sfikas, Nikolaos
    von Rosenstiel, Philipp
    Kappos, Ludwig
    JOURNAL OF NEUROLOGY, 2015, 262 (12) : 2627 - 2634
  • [46] Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis
    Xavier Montalban
    Giancarlo Comi
    Jack Antel
    Paul O’Connor
    Ana de Vera
    Malika Cremer
    Nikolaos Sfikas
    Philipp von Rosenstiel
    Ludwig Kappos
    Journal of Neurology, 2015, 262 : 2627 - 2634
  • [47] Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab
    Treon, Steven P.
    Soumerai, Jacob D.
    Hunter, Zachary R.
    Patterson, Christopher J.
    Ioakimidis, Leukothea
    Kahl, Brad
    Boxer, Michael
    BLOOD, 2011, 118 (02) : 276 - 281
  • [48] Emapalumab, a Fully Human Anti-Interferon Gamma Monoclonal Antibody, in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Long-Term Follow-up of a Phase 2/3 Study
    Jordan, Michael B.
    Allen, Carl
    Rao, Anupama
    Rizzari, Carmelo
    Cesaro, Simone
    Putti, Maria Caterina
    Sevilla, Julian
    de Min, Cristina
    Ballabio, Maria
    Asnaghi, Veronica
    Stoltenberg, Anna
    Kanceva, Radmila
    Locatelli, Franco
    BLOOD, 2023, 142
  • [49] A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
    Sawas, Ahmed
    Farber, Charles M.
    Schreeder, Marshall T.
    Khalil, Mazen Y.
    Mahadevan, Daruka
    Deng, Changchun
    Amengual, Jennifer E.
    Nikolinakos, Petros G.
    Kolesar, Jill M.
    Kuhn, John G.
    Sportelli, Peter
    Miskin, Hari P.
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (02) : 243 - 253
  • [50] Long-term course of patients in neurological rehabilitation Phase B. Results of the 6-year follow-up in a multicenter study
    Pohl, M.
    Berger, K.
    Ketter, G.
    Krusch, C.
    Pause, M.
    Puschendorf, W.
    Schaupp, M.
    Schleep, J.
    Spranger, M.
    Steube, D.
    Scheidtmann, K.
    Mehrholz, J.
    NERVENARZT, 2011, 82 (06): : 753 - +
12345